12th October 2017 -

Foundation for Neglected Disease Research is happy to announce that its partner, TB Alliance has initiated the Phase 1 clinical trial of TBA-7371, a novel DprE1 inhibitor, for the treatment of tuberculosis. With no pre-existing resistance or cross-resistance with other TB drugs, TBA-7371 could have significant potential in the treatment of TB.